Suppr超能文献

合成孕激素对雄激素受体信号传导的干扰可能会增加患乳腺癌的风险。

Disruption of androgen receptor signaling by synthetic progestins may increase risk of developing breast cancer.

作者信息

Birrell Stephen N, Butler Lisa M, Harris Jonathan M, Buchanan Grant, Tilley Wayne D

机构信息

Dame Roma Mitchell Cancer Research Laboratories, The University of Adelaide, Hanson Institute, PO Box 14, Rundle Mall, South Australia, 5000, Australia.

出版信息

FASEB J. 2007 Aug;21(10):2285-93. doi: 10.1096/fj.06-7518com. Epub 2007 Apr 5.

Abstract

There is now considerable evidence that using a combination of synthetic progestins and estrogens in hormone replacement therapy (HRT) increases the risk of breast cancer compared with estrogen alone. Furthermore, the World Health Organization has recently cited combination contraceptives, which contain synthetic progestins, as potentially carcinogenic to humans, particularly for increased breast cancer risk. Given the above observations and the current trend toward progestin-only contraception, it is important that we have a comprehensive understanding of how progestins act in the millions of women worldwide who regularly take these medications. While synthetic progestins, such as medroxyprogesterone acetate (MPA), which are currently used in both HRT and oral contraceptives were designed to act exclusively through the progesterone receptor, it is clear from both clinical and experimental settings that their effects may be mediated, in part, by binding to the androgen receptor (AR). Disruption of androgen action by synthetic progestins may have serious deleterious side effects in the breast, where the balance between estrogen signaling and androgen signaling plays a critical role in breast homeostasis. Here, we review the role of androgen signaling in the normal breast and in breast cancer and present new data demonstrating that androgen receptor function can be perturbed by low doses of MPA, similar to doses achieved in serum of women taking HRT. We propose that the observed excess of breast malignancies associated with combined HRT may be explained, in part, by synthetic progestins such as MPA acting as endocrine disruptors to negate the protective effects of androgen signaling in the breast. Understanding the role of androgen signaling in the breast and how this is modulated by synthetic progestins is necessary to determine how combined HRT alters breast cancer risk, and to inform the development of optimal preventive and treatment strategies for this disease.

摘要

现在有大量证据表明,与单独使用雌激素相比,在激素替代疗法(HRT)中联合使用合成孕激素和雌激素会增加患乳腺癌的风险。此外,世界卫生组织最近指出,含有合成孕激素的复方避孕药对人类具有潜在致癌性,尤其是会增加患乳腺癌的风险。鉴于上述观察结果以及目前仅使用孕激素避孕的趋势,我们全面了解孕激素在全球数百万定期服用这些药物的女性体内的作用方式非常重要。虽然目前用于HRT和口服避孕药的合成孕激素,如醋酸甲羟孕酮(MPA),被设计为仅通过孕激素受体起作用,但从临床和实验环境中都可以清楚地看出,它们的作用可能部分是通过与雄激素受体(AR)结合来介导的。合成孕激素对雄激素作用的干扰可能会在乳腺中产生严重的有害副作用,在乳腺中,雌激素信号和雄激素信号之间的平衡在乳腺内环境稳定中起着关键作用。在这里,我们回顾雄激素信号在正常乳腺和乳腺癌中的作用,并展示新的数据,证明低剂量的MPA(类似于服用HRT的女性血清中达到的剂量)可以干扰雄激素受体功能。我们提出,观察到的与联合HRT相关的乳腺恶性肿瘤过多现象,可能部分是由于合成孕激素如MPA作为内分泌干扰物,抵消了乳腺中雄激素信号的保护作用。了解雄激素信号在乳腺中的作用以及合成孕激素如何调节这种作用,对于确定联合HRT如何改变乳腺癌风险以及为该疾病制定最佳预防和治疗策略至关重要。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验